As of January 1998, l l of the 12 provinces and territories had some form of publicly funded pneumococcal immunization program. However, differences exist between what individual provinces and territoriesis include in these programs. One province and the two territories include all risk groups as defined by NACI, including healthy individuals 65 years of age and older. Three other provinces include all high risk groups except for healthy persons 65 years of age and older. Two provinces include only some of the high risk groups, and one province offers vaccine only to individuals over 65 years of age. ln addition, two provinces primarily target persons in long term care facilities. Four provinces, including the one that does not currently have a publicly funded pneumococcal immunization program, are anticipating major program expansion in 1998.
In the 11 provinces and territories with pneumococcal immunization programs , the vaccine is administered by both public health and private physicians. In seven of the provinces and territories, both groups give the vaccine. In one province and one of the territories, public health is solely responsible for vaccine delivery, and, in two other provinces, it is exclusively the responsibility of private physicians.
In the provinces where all high risk groups are not currently covered by publicly funded pneumococcal immunization programs , three stated that cost was the major deterrent. Only one province considered pneumococcal disease a low priority. In two provinces, proposals had been put forth for pneumococcal immunization programs; however, they had yet to be accepted. No province or territory identified vaccine effectiveness or cost effectiveness as a barrier.
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coccal vaccination programs across Canada Nationally, information on pneumococcal mening1t1s is published in the Notifiable Diseases Annual Summa,y (3); however, only 10 provinces and territories collect and submit these data. In seven jurisdictions, this surveillance activity is limited to pneumococcal meningitis. In two of the provinces and one territory, surveillance also includes pneumococcal bacteremia. Two provinces plan to expand surveillance in the future to include all invasive pneumococcal disease.
Changes are occurring in Canada with regard to the priority given for surveillance and prevention of pneumococcal infections, particulary among the elderly. As pneumococcal vaccine Can J Infect Dis Vol 10 Suppl A January/ February 1999 programs develop across Canada, more work will need to be done to monitor vaccine uptake by the targeted groups and define the effectiveness of the programs in reaching persons at risk.
